GUMDROP : JHMI J1066 A Phase I and IIa Study of Safety and Efficacy of Alpharadin with docetaxel in patients with bone metastases from castration-resistant prostate cancer

Created by Channing Paller, last modified on Apr 14, 2012

Description:

This study will determine the maximum tolerated dose and test the safety of alpharadin in metastatic castrate resistant prostate cancer patients who meet the following eligibility requirements: testosterone = 50 ng/dL OR failure to respond to anti-androgen withdrawal OR PSA progression (2 consecutive rises within 6 mo) OR =2 new bone lesions; =2 confirmed bone metastases in 12 weeks; NO prior hemibody radiotherapy; NO prior radiotherapy for bone mets; =10 prior docetaxel infusions

Link:

http://clinicaltrials.gov/ct2/show/NCT01106352

 

Site:

Johns Hopkins Hospital

Principal Investigator:

Hans Hammers, M.D.